<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02644707</url>
  </required_header>
  <id_info>
    <org_study_id>ARISTOTLE UNIVERSITY</org_study_id>
    <nct_id>NCT02644707</nct_id>
  </id_info>
  <brief_title>Selenium Supplementation in Youths With Autoimmune Thyroiditis</brief_title>
  <acronym>THYROSEL</acronym>
  <official_title>L-selenomethionine Supplementation in Children and Adolescents With Autoimmune Thyroiditis: a Randomized Blind Placebo-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aristotle University Of Thessaloniki</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aristotle University Of Thessaloniki</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate whether the supplementation of organic selenium at the &quot;adult&quot; dose (200 mcg
      per day in the form of L-selenomethionine) has a favorable impact on thyroid function,
      including the titer of anti-thyroid antibodies [Anti-thyroid peroxidase (anti-TPO) and
      Anti-thyroglobulin (anti-Tg) antibodies], in children and adolescents with autoimmune
      thyroiditis (AT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Selenium in the form of seleno-cysteine is an essential component of enzymes that
      remove toxic substances from the body, such as glutathione peroxidase (GPX) in thyroid cells
      as well as seleno-dependent iodothyronine deiodinase that catalyses extra-thyroidal
      production of triiodothyronine (T3). In general, selenium deficiency may influence production
      of free radicals, conversion of thyroxine T4 to T3, cytokine production and immune
      mechanisms. Thus, it has been previously suggested that its supplementation may have a
      beneficial effect in patients with autoimmune thyroiditis, especially in those with increased
      inflammatory activity and a higher antibody titer. Although the two studies that have so far
      been conducted in pediatric populations demonstrated no significant effect of selenium
      administration on the titre of antibodies, the researchers did administer selenium either in
      the form of inorganic sodium selenite at the &quot;adult&quot; dose (100-200 mcg daily) or in the form
      of organic L-selenomethionine at the reduced dose (50 mcg daily). Therefore, to the best of
      our knowledge, selenium supplementation in the form of organic L-selenomethionine at the
      &quot;adult&quot; dose (200 mcg daily) has not been investigated in children and adolescents with
      autoimmune thyroiditis (AT) so far.

      Objective: Our aim is to investigate whether the supplementation of organic selenium at the
      &quot;adult&quot; dose (200 mcg per day in the form of L-selenomethionine) has a favorable impact on
      thyroid function, including the titer of anti-thyroid antibodies (thyroid-peroxidase antiTPO,
      and thyroglobulin -antiTg- antibodies), in children and adolescents with autoimmune
      thyroiditis (AT).

      Design and Methods: This is a randomized blinded placebo-controlled clinical trial of
      selenium supplementation versus placebo in children and adolescents with autoimmune
      thyroiditis (AT). The trial will include 100 consecutive participants (50 participants in
      each arm) from the Unit of Pediatric Endocrinology of the 4th Department of Pediatrics,
      Medical School, Aristotle University of Thessaloniki, Greece. The patients will be informed
      and given their written consent to be included in the study. The subjects will then be
      randomized to receive either organic selenium in the form of L-selenomethionine at the dose
      of 200mcg daily (intervention group) or placebo (control group) for 6 months. Both groups
      will receive oral tablets (one daily), which will be identical in appearance, taste and smell
      and will differ only in the type of active substance (L-selenomethionine or placebo). Six
      months of additional follow-up will lead to trial duration of 12 months. The experimental
      supplement will be given by the Pharmaceutical company marketing the product SEMED200Â®
      (INTERMED Pharmaceutical Laboratories). In all participants, determination of the
      concentrations of thyroid-stimulating hormone (TSH), free thyroxine (fT4), thyroid peroxidase
      antibodies (TPOAb), thyroglobulin antibody (TgAb) will be made at four times (0, 3, 6 and 12
      months). Thyroid volume and morphology will also be sonographically evaluated in three times
      (0, 6 and 12 months). Serum selenium levels in the form of selenomethionine will also be
      determined once (at the beginning of the study).

      Time-schedule: January- February 2015: protocol preparation. March 2015: first participant's
      first visit. March 2016: last participant's first visit. September 2016: last participant's
      last visit. September - October 2016: analysis of biological samples and data, preparation of
      manuscripts, March 2017: last participant's completion of follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in titer of thyroid autoantibodies (thyroid-peroxidase -AntiTPO-, and thyroglobulin -antiTg- antibodies)</measure>
    <time_frame>0,3,6,12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of serum selenium levels</measure>
    <time_frame>0 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in state of thyroid function (Euthyroid or Hypothyroid)</measure>
    <time_frame>0,6,12 months</time_frame>
    <description>Hypothyroid state will be defined as the state of abnormal thyroid function that requires substitution treatment with L-thyroxine; in particular, if thyroid-stimulating hormone (TSH) serum levels are greater than 5 micro-units per milliliter (mcU/ml) and/or the levels of fT4 or fT3 are decreased. Otherwise the state will be considered as euthyroid.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in thyroxine dose per kg per day</measure>
    <time_frame>0,6,12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in thyroid volume measured by ultrasonography</measure>
    <time_frame>0,6,12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Autoimmune Thyroiditis</condition>
  <arm_group>
    <arm_group_label>L-selenomethionine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A group randomized to receive organic selenium in the form of L-selenomethionine at the dose of 200mcg daily (intervention group) for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A group randomized to receive placebo (control group) for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>L-selenomethionine</intervention_name>
    <description>The group will be randomized to receive organic selenium in the form of L-selenomethionine at the dose of 200mcg daily (intervention group) for 6 months</description>
    <arm_group_label>L-selenomethionine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The group will be randomized to receive placebo (control group) for 6 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: A positive titer of antithyroid peroxidase (anti-TPO) or
        antithyroglobulin (anti-Tg) antibodies (TPO and / or Tg&gt; 60 IU / ml) and at least one of:

          -  Abnormal thyroid function that requires substitution treatment with L-thyroxine (TSH &gt;
             5 micro-units per milliliter (mcU/ml) and decreased or normal levels of fT4 or fT3)

          -  Increased volume of thyroid gland (goiter)

          -  Morphological changes on ultrasound of the thyroid gland

        Exclusion Criteria:

          -  Presence of another chronic disease or autoimmune disease or being under medication

          -  Age of diagnosis above 18 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Assimina Galli-Tsinopoulou, Assoc Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unit of Pediatric Endocrinology, Diabetes and Metabolism - 4th Department of Pediatrics, Medical School of Aristotle University of Thessaloniki, 56403 Thessaloniki, Greece</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Assimina Galli-Tsinopoulou, Assoc Prof</last_name>
    <phone>+302310991537</phone>
    <email>agalli@auth.gr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ioannis Kyrgios, MD, MSc</last_name>
    <phone>+302310991537</phone>
    <email>ikyrgios@yahoo.gr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Unit of Pediatric Endocrinology, Diabetes and Metabolism-4th Department of Pediatrics, Medical School of Aristotle University of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <zip>56403</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Assimina Galli-Tsinopoulou, Assoc Prof</last_name>
      <phone>+302310991537</phone>
      <email>agalli@auth.gr</email>
    </contact>
    <contact_backup>
      <last_name>Ioannis Kyrgios, MD,MSc</last_name>
      <phone>+302310991537</phone>
      <email>ikyrgios@yahoo.gr</email>
    </contact_backup>
    <investigator>
      <last_name>Assimina Galli-Tsinopoulou, Assoc Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ioannis Kyrgios, MD,MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eleni P Kotanidou, MD,MSc,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aikaterini Dimopoulou, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Angeliki Kleisarchaki, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Konstantina Mouzaki, MD,MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>Karanikas G, Schuetz M, Kontur S, Duan H, Kommata S, Schoen R, Antoni A, Kletter K, Dudczak R, Willheim M. No immunological benefit of selenium in consecutive patients with autoimmune thyroiditis. Thyroid. 2008 Jan;18(1):7-12. doi: 10.1089/thy.2007.0127.</citation>
    <PMID>18302514</PMID>
  </reference>
  <results_reference>
    <citation>Anastasilakis AD, Toulis KA, Nisianakis P, Goulis DG, Kampas L, Valeri RM, Oikonomou D, Tzellos TG, Delaroudis S. Selenomethionine treatment in patients with autoimmune thyroiditis: a prospective, quasi-randomised trial. Int J Clin Pract. 2012 Apr;66(4):378-83. doi: 10.1111/j.1742-1241.2011.02879.x. Epub 2012 Feb 22.</citation>
    <PMID>22356267</PMID>
  </results_reference>
  <results_reference>
    <citation>Bonfig W, GÃ¤rtner R, Schmidt H. Selenium supplementation does not decrease thyroid peroxidase antibody concentration in children and adolescents with autoimmune thyroiditis. ScientificWorldJournal. 2010 Jun 1;10:990-6. doi: 10.1100/tsw.2010.91.</citation>
    <PMID>20526530</PMID>
  </results_reference>
  <results_reference>
    <citation>Duntas LH, Mantzou E, Koutras DA. Effects of a six month treatment with selenomethionine in patients with autoimmune thyroiditis. Eur J Endocrinol. 2003 Apr;148(4):389-93.</citation>
    <PMID>12656658</PMID>
  </results_reference>
  <results_reference>
    <citation>Eskes SA, Endert E, Fliers E, Birnie E, Hollenbach B, Schomburg L, KÃ¶hrle J, Wiersinga WM. Selenite supplementation in euthyroid subjects with thyroid peroxidase antibodies. Clin Endocrinol (Oxf). 2014 Mar;80(3):444-51. doi: 10.1111/cen.12284. Epub 2013 Jul 31.</citation>
    <PMID>23844613</PMID>
  </results_reference>
  <results_reference>
    <citation>GÃ¤rtner R, Gasnier BC, Dietrich JW, Krebs B, Angstwurm MW. Selenium supplementation in patients with autoimmune thyroiditis decreases thyroid peroxidase antibodies concentrations. J Clin Endocrinol Metab. 2002 Apr;87(4):1687-91.</citation>
    <PMID>11932302</PMID>
  </results_reference>
  <results_reference>
    <citation>Krysiak R, Okopien B. The effect of levothyroxine and selenomethionine on lymphocyte and monocyte cytokine release in women with Hashimoto's thyroiditis. J Clin Endocrinol Metab. 2011 Jul;96(7):2206-15. doi: 10.1210/jc.2010-2986. Epub 2011 Apr 20.</citation>
    <PMID>21508145</PMID>
  </results_reference>
  <results_reference>
    <citation>Mazokopakis EE, Papadakis JA, Papadomanolaki MG, Batistakis AG, Giannakopoulos TG, Protopapadakis EE, Ganotakis ES. Effects of 12 months treatment with L-selenomethionine on serum anti-TPO Levels in Patients with Hashimoto's thyroiditis. Thyroid. 2007 Jul;17(7):609-12.</citation>
    <PMID>17696828</PMID>
  </results_reference>
  <results_reference>
    <citation>Nacamulli D, Mian C, Petricca D, Lazzarotto F, Barollo S, Pozza D, Masiero S, Faggian D, Plebani M, Girelli ME, Mantero F, Betterle C. Influence of physiological dietary selenium supplementation on the natural course of autoimmune thyroiditis. Clin Endocrinol (Oxf). 2010 Oct;73(4):535-9. doi: 10.1111/j.1365-2265.2009.03758.x.</citation>
    <PMID>20039895</PMID>
  </results_reference>
  <results_reference>
    <citation>Negro R, Greco G, Mangieri T, Pezzarossa A, Dazzi D, Hassan H. The influence of selenium supplementation on postpartum thyroid status in pregnant women with thyroid peroxidase autoantibodies. J Clin Endocrinol Metab. 2007 Apr;92(4):1263-8. Epub 2007 Feb 6.</citation>
    <PMID>17284630</PMID>
  </results_reference>
  <results_reference>
    <citation>Onal H, Keskindemirci G, Adal E, Ersen A, Korkmaz O. Effects of selenium supplementation in the early stage of autoimmune thyroiditis in childhood: an open-label pilot study. J Pediatr Endocrinol Metab. 2012;25(7-8):639-44.</citation>
    <PMID>23155687</PMID>
  </results_reference>
  <results_reference>
    <citation>Toulis KA, Anastasilakis AD, Tzellos TG, Goulis DG, Kouvelas D. Selenium supplementation in the treatment of Hashimoto's thyroiditis: a systematic review and a meta-analysis. Thyroid. 2010 Oct;20(10):1163-73. doi: 10.1089/thy.2009.0351. Review.</citation>
    <PMID>20883174</PMID>
  </results_reference>
  <results_reference>
    <citation>Turker O, Kumanlioglu K, Karapolat I, Dogan I. Selenium treatment in autoimmune thyroiditis: 9-month follow-up with variable doses. J Endocrinol. 2006 Jul;190(1):151-6.</citation>
    <PMID>16837619</PMID>
  </results_reference>
  <results_reference>
    <citation>van Zuuren EJ, Albusta AY, Fedorowicz Z, Carter B, Pijl H. Selenium supplementation for Hashimoto's thyroiditis. Cochrane Database Syst Rev. 2013 Jun 6;(6):CD010223. doi: 10.1002/14651858.CD010223.pub2. Review.</citation>
    <PMID>23744563</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhu L, Bai X, Teng WP, Shan ZY, Wang WW, Fan CL, Wang H, Zhang HM. [Effects of selenium supplementation on antibodies of autoimmune thyroiditis]. Zhonghua Yi Xue Za Zhi. 2012 Aug 28;92(32):2256-60. Chinese.</citation>
    <PMID>23158484</PMID>
  </results_reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 29, 2015</study_first_submitted>
  <study_first_submitted_qc>December 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2016</study_first_posted>
  <last_update_submitted>December 30, 2015</last_update_submitted>
  <last_update_submitted_qc>December 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aristotle University Of Thessaloniki</investigator_affiliation>
    <investigator_full_name>Assimina Galli-Tsinopoulou</investigator_full_name>
    <investigator_title>ASSSOCIATE PROFESSOR</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroiditis</mesh_term>
    <mesh_term>Thyroiditis, Autoimmune</mesh_term>
    <mesh_term>Hashimoto Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Selenium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

